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Abstract
Background: Since a milestone work on Neisseria meningitidis B, Reverse Vaccinology has strongly
enhanced the identification of vaccine candidates by replacing several experimental tasks using in
silico prediction steps. These steps have allowed scientists to face the selection of antigens from the
predicted proteome of pathogens, for which cell culture is difficult or impossible, saving time and
money. However, this good example of bioinformatics-driven immunology can be further
developed by improving in silico steps and implementing biologist-friendly tools.
Results: We introduce NERVE (New Enhanced Reverse Vaccinology Environment), an user-
friendly software environment for the in silico identification of the best vaccine candidates from
whole proteomes of bacterial pathogens. The software integrates multiple robust and well-known
algorithms for protein analysis and comparison. Vaccine candidates are ranked and presented in a
html table showing relevant information and links to corresponding primary data. Information
concerning all proteins of the analyzed proteome is not deleted along selection steps but rather
flows into an SQL database for further mining and analyses.
Conclusion: After learning from recent years' works in this field and analysing a large dataset,
NERVE has been implemented and tuned as the first available tool able to rank a restricted pool
(~8–9% of the whole proteome) of vaccine candidates and to show high recall (~75–80%) of known
protective antigens. These vaccine candidates are required to be "safe" (taking into account
autoimmunity risk) and "easy" for further experimental, high-throughput screening (avoiding
possibly not soluble antigens). NERVE is expected to help save time and money in vaccine design
and is available as an additional file with this manuscript; updated versions will be available at http:/
/www.bio.unipd.it/molbinfo.
Background
Reverse Vaccinology (RV) is one of the best examples of
how Bioinformatics can boost Molecular Immunology.
The conventional approach to design vaccines requires
pathogen's cultivation and dissection of its main compo-
nents before testing their ability to elicit protective immu-
nity. RV's novelty consists in starting the search for
immunogenic antigens from in silico analyses of the path-
ogen's genome instead of culturing the microorganism
[1]. This allows scientists to save time and money while
facing pathogens for which cell culture is difficult or
impossible. RV potentially permits researchers to select, in
addition to most in vivo expressed antigens (the easiest
ones to purify), any protein encoded by the genome of a
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pathogen. RV is less helpful with eucaryotes due to com-
plexities of cellular and tissue organization, and it is more
effective with prokaryotes, extra- and intracellular.
Indeed, the production of specific antibodies can boost
immunity not only against extracellular pathogens, usu-
ally controlled by Th2-polarized responses, but also
against either obligate or facultative intracellular ones,
usually controlled by Th1-polarized responses. Even these
latter pathogens are susceptible to humoral immunity
during the extracellular phases of their infectious cycle
and are made vulnerable by antibody cross-linking that
modifies the intracellular milieu through signaling [2,3].
The extracellular pathogen, Neisseria meningitidis sero-
group B, stands as a milestone for RV. From its genome,
Pizza and coworkers selected 570 out of 2158 predicted
ORFs for protein expression as those meant to be new,
surface-exposed antigens [4]. 350 ORFs were successfully
cloned, expressed in Escherichia coli and tested in a variety
of assays. In the end, five proteins were found to satisfy
criteria of surface exposure, conservation/expression in all
strains as well as a significant titer in serum bactericidal
assays. This work induced further research of other patho-
gens in the same way: Porphyromonas gingivalis [5], Strepto-
coccus pneumoniae [6], Chlamydia pneumoniae [3], Bacillus
anthracis [7] and group B streptococci [8]. Enhancing such
a genome-based approach with a trascriptome-based one
– through the use of DNA microarrays – shows whether,
when and to what extent antigens are expressed, thus
identifying those highly expressed during infection proc-
esses [9]. Finally, proteomics, although expensive and
laborious, can verify in silico prediction of membrane
composition [10].
We focused on the selection of the in silico vaccine candi-
dates (VCs) from the list of predicted proteins to address
two issues: the possibility (i) of automatizing the process
with new criteria of analyses and (ii) of reducing the per-
centage of VCs to less than the 20–30% reported until
now [11]. Indeed, the real goal of in silico selection is to
choose the minimal number of VCs sufficient to find pro-
tective antigens (PAs) during experimental phases, thus
designing a vaccine that conserves time and money.
Therefore, it has to be stressed that obtaining a high recall
of PAs in a very small number of selected VCs is more con-
venient than trying to find all possible PAs. According to
this approach it is more productive to select the PAs that
will most likely be easily expressed. This reduces the risk
of experimental troubles. The main cause of failed cloning
and expression of 250 out of 600 VCs from Neisseria men-
ingitidis B was the presence of more than one transmem-
brane spanning region (TM) [12]. Thus, we decided to
have no more than two predicted TMs as an a priori
requirement. Of course, viable VCs can be missed because
of such a filter; the extracellular loops of multispanning
membrane proteins can actually be significant targets
especially if reasonably large. Hence, one may focus on
fragments likely to be exposed and accessible to antibod-
ies rather than the entire protein in order to overcome
eventual cloning and expression problems. Although such
a "local" approach is reasonable, we designed the software
to select entire antigens for experimental challenges rather
than hazarding fine predictions that may not correspond
to in vivo conditions.
Choosing such a conservative way to face vaccine design
inevitably implies missing some PAs, but this is a small
price to reach a valuable compromise. Even selecting only
surface antigens may imply missing non-surface PAs. Yet
discarding non-surface-exposed predicted antigens,
thereby forwarding further bioinformatic analyses on
selected ones, proved successful. However, to mimimize
the risk of loosing good VCs, we stored up information
concerning analytical steps for each sequence without dis-
tinction: the final output presents only selected VCs, but
information concerning all other proteins is retained. VCs
are presented with corresponding integrated analyses. In
order to "rationalize" selection step, we took into account
the importance of avoiding antigens that can potentially
cause autoimmunity in man [13]. Since Major Hystocom-
patibility Complex (MHC) ligands can be really short (as
few as eight residues); this problem may rise also from
antigens sharing weak global similarity with host pro-
teins. Addressing such a question on a proteomic scale
would make manual management of bioinformatic anal-
yses impossible.
We report here on a new, fully automated RV system,
developed to predict best VCs from bacterial proteomes
(inferred by completely sequenced genomes and publicly
available) and to manage and show data by user-friendly
output.
Implementation
NERVE software pipeline is presented in figure 1. NERVE
is composed of eight Perl scripts. A script named "NERVE"
leads the user through text-interface configuration. Once
this is successfully completed, the script starts and man-
ages the whole process that can be roughly divided in two
parts: the first in which all data is produced and stored
and the second in which a restricted part of this data is
selected. The acquisition of data is performed by six differ-
ent analytical steps, each forwarded by a special script and
each in turn screens the whole proteome indistinctly. All
the information produced is stored both in a MySQL table
and in text files organized in special subdirectories. Once
production and storage of data is completed, another
script selects a restricted number of entries from the
MySQL table (restriction) and ranks them in a user-
friendly html table (ranking). Restriction is performed byBMC Biotechnology 2006, 6:35 http://www.biomedcentral.com/1472-6750/6/35
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NERVE software pipeline Figure 1
NERVE software pipeline. The process can be divided into two parts: data production and storage (top) and data selection 
(bottom). Six different scripts screen the entire proteome to mine and infer information that flows into a MySQL table. A sev-
enth script uses four filters (LOC, localization; TOP topology; PAD, probability of being adhesin; SHP, similarity to human pro-
teins) and analyzes values created by steps 1 through 5 to select and rank VCs that are then presented in a html table with links 
to relevant data.BMC Biotechnology 2006, 6:35 http://www.biomedcentral.com/1472-6750/6/35
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four integrated filters and is based on values created by
steps 1 to 4. Filters LOC and TOP select non cytoplasmic
antigens containing no more than two TMs (NERVE a pri-
ori  requirements). Subsequently, based on empirical
threshold values, filters PAD and SHP discard antigens
that show a low probability of being adhesins and/or a
significant similarity to human proteins. To set these val-
ues, NERVE was tuned on ten entire proteomes containing
known immunogens; we chose the pair of threshold val-
ues that gave the best compromise between restrictivness
and immunogen recall. After restriction, NERVE uses val-
ues created by step 5 to rank the antigens extracted by the
filters. An html table presents this restricted and ranked
pool of VCs, showing in six columns the values created by
the analytical steps. Entries and data are linked to the cor-
responding textfiles, thus providing the user with com-
plete information.
Results and discussion
The system we created predicts the best VCs starting from
the flatfile proteome of a prokaryotic pathogen. It for-
wards six proteome-wide analyses that mine and save data
in text files and in an automatically generated MySQL
table. The table will contain as many records of extracted
information as the number of sequences in thirteen fields.
The best VCs are finally selected and are shown in a user-
friendly html table reporting seven out of the thirteen
fields, linked to the textfile-information that they summa-
rize.
The first proteome scannings assign each sequence three
predictions: (i) subcellular localization, (ii) adhesin prob-
ability and (iii) topology, using the algorithms PSORTb
2.0 [14], SPAAN [15] and HMMTOP [16] respectively.
Indeed, surface-exposed proteins such as outer membrane
proteins and especially adhesins, are ideal targets for vac-
cine development [4,17]. At the same time, the presence
of more than one TM in many of these VCs, proved prob-
lematic in cloning and expression phases of RV (see intro-
duction) [12]. This clearly shows how predicting number
of TMs is potentially a crucial step in saving time and
money for subsequent experimental tests. The fourth step
addresses the problem of sharing similarity regions
between pathogen and host proteins. It is well known that
in vaccine development this can either cause low immune
response/tolerance or autoimmunity [13]. We have cho-
sen the algorithm BLAST to compare each pathogen's
sequence as a query against the human proteome [18].
Local alignment is suitable for this task because potential
MHC ligands – the ones we search for to help predict
potential interferences (tolerance or autoimmunity) with
the immune system – can be very short (~9 residues) [19].
Thus, the script scans alignments, extracting each
sequence fragment (shared peptide, SP) that shows no
more than three "positives" (compatible substitutions)
and one "mismatch" (not compatible substitution) per
nine-residues (minimal length required) window. In this
way we not only take into account MHC II, commonly
involved in presentation of exogenous antigens, but also
MHC I, involved in cross-presentation [20,21]. These set-
tings can be changed at the start of the manager pro-
gramme according to the user's preferences. Once an SP is
found, corresponding bacterial and human sequences are
reported with their position in the protein and the availa-
ble description for the human entry in the MySQL table
and the text file. Once this fourth step is complete, each
pathogen's sequence is assigned to a file, named as its
accession, and sent to four new fields in the MySQL data-
base. The first two of these fields show query length and
number of mined SPs. The third one reports four features
for each SP: position, amino acid sequence, occurrence
and "MHC ligand". This last feature is expressed as either
"positive" or "negative" depending on the results from a
screening of human MHC ligands derived from the data-
base MHCPEP [21]. These MHC ligands do not necessar-
ily correspond to T-epitopes. It would be more
advantageous to use a T-epitope prediction tool, but as of
now there is no such tool available for standalone use. In
addition, since the number of unknown MHC ligands is
possibly high, "positive" is a "necessary-but-not-suffi-
cient" condition, whereas "negative" stands as an absence
of evidence rather than an evidence of absence. The fourth
field reports the aggregate number of amino acid residues
from all peptides.
The fifth step allows the user to compare the pathogen's
proteome to any other from a different strain/serogroup.
Indeed, inferring conservation of each sequence may be
helpful in selecting the best VCs as the more an immuno-
gen is conserved, the more protective the vaccine
becomes. The way in which we compare two pathogen
proteomes is the same process we use to compare patho-
gen versus human proteomes; all regions potentially capa-
ble of binding MHC ligands are searched for in an
analogous way. Although this step is not compulsory, it
allows NERVE to rank VCs from most to least represented
in the compared prokaryotic proteome in the html table
presenting the selection set (see below). When possible
the sixth step assigns an homology-driven, function pre-
diction to each VC. For instance, this allows one to focus
on a VC that shows strong similarity to either known vir-
ulence factors or strong immunogens. NERVE uses
BLASTp algorithm to compare each sequence to the Uni-
prot database. According to Ariel et al. (2003) [7], the
script adopts these parameters: e-value ≤1e-10 and (align-
ment extension)/(query length) ≥ 0.8. This allows NERVE
to attribute to the sequence the subject's most similar
function as a query putative function, reported in a further
special MySQL column – if no hits are found, the notice
"no sufficient similarity found for function inference" isBMC Biotechnology 2006, 6:35 http://www.biomedcentral.com/1472-6750/6/35
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shown. The putative function is then saved in a special
text file with the corresponding score and e-value. This last
step completes the MySQL database, which in total con-
tains thirteen fields complete with all the information
produced along the six analyses. Although each type of
information may be retrieved at any time, the final script
presents the best VCs in a user-friendly html table. This
displays accession numbers and six out of the eleven
MySQL fields, linking them to text files containing sum-
marized data (figure 2).
For final selection of VCs, NERVE uses feature-based, a pri-
ori requirements to discard proteins that are likely to waste
time and money during the experimental tasks (such as
those with > 2 TMs) and to exclude non-surface antigens
such as cytoplasmic/inner membrane proteins (see intro-
duction for rationale). To further improve final selection
efficiency, NERVE considers two characteristics for empir-
ical tuning: the probability that a sequence is an adhesin
and the presence of regions common to human proteins.
Variation of threshold values for such features along iter-
ative analysis of a known data set (ten proteomes, from
both Gram+ and Gram-, both extra- and intracellular bac-
teria) allowed NERVE to define restricted VC pools (aver-
age size: 8.17% proteome sequences, figure 3) including a
high number (33/42 = 78.6%) of the described PAs that
fulfill NERVE a priori requirements (see table 1: selected
PAs are underlined; PAs not fulfilling NERVE a priori
requirements are not shown). Settings consistently con-
firmed themselves as reliably effective – in terms of both
PA recall and selection restrictiveness – when tested on six
further proteomes (from both Gram+ and Gram-, both
extra- and intracellular bacteria). In fact, most (22/29 =
75.9%) of the described PAs fulfilling NERVE a priori
requirements (see table 2: same PAs representation crite-
ria as in table 1) were included in 9.32% whole proteomes
average size pools (figure 4).
Conclusion
RV stands as a turning stone in Vaccinology. It shows how
powerful and useful Bioinformatics can be in the post-
genomic era. Creating a tool specifically designed to
automatize in silico steps not only makes RV really availa-
ble but also time and cost efficient. Indeed, NERVE was
conceived to combine automation with an exhaustive
treatment of VCs selection task by implementing and inte-
grating six different kinds of analyses. Its modular struc-
ture allows further development of new, additional steps
as well as the refinement of existing modules. This would
improve the compromise between VC selection restrictiv-
ness and PA recall. Another goal was to avoid loosing
information, thereby giving the user the chance to recover
all data mined by NERVE for further investigation. For
instance, recovered data regarding shared similarity
regions between VCs and human proteins may be of help
when taking into account possible occurrences of either
tolerance or autoimmunity.
Finally, the NERVE prediction system proved – on a large
number of bacterial proteomes – to be reliably effective in
selecting very restricted VC pools that are characterized by
a high recall (75–80%) of PAs. In particular these results
narrow VC pool restriction from the reported 20–30% to
an improved 8–9% of proteome sequences. NERVE's
attempt to save time and money is also mediated by selec-
tion criteria, meant to facilitate crucial experimental steps,
the protein cloning and expression phases. Last but not
least, NERVE's user-friendly format and easily interpreta-
ble output should further aid researchers in designing
subunit vaccines against bacterial pathogens.
Flow-chart of NERVE working process Figure 2
Flow-chart of NERVE working process. Amino acid 
sequences from the whole bacterial proteome undergo six 
analytical steps: prediction of subcellular localization (1), cal-
culation of probability of being adhesin (2), identification of 
TM domains (3), comparison to the proteome of Homo sapi-
ens (4) and to that of a pathogen selected by the user (5), 
assignment of a putative function (6). Each of these steps 
stores data mined in an SQL database. After filtering and 
ranking, the best VCs are presented in a user-friendly html 
table (see figure 1 and Results and Discussion for details).BMC Biotechnology 2006, 6:35 http://www.biomedcentral.com/1472-6750/6/35
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Table 2: Test of NERVE settings on another dataset including 6 proteomes.
Pathogen Strain Known protective antigens (non 
cytoplasmic, ≤2 TMs)
Primary accession numbers 
(Uniprot database)
References
Staphylococcus aureus MW2 Spa, PBP2A, ClfA, collagen-binding, 
fibronectin-binding, enterotoxin A, alpha-
toxin
Q8NXT0 Q8NWP5 P0A0L1 Q8NUH0 
Q8NUU7 Q8NX49 Q8NXJ1
[37–39]
Neisseria gonorrhoeae ATCC 700825 PorB, TbpA, TbpB Q5F5V7 Q5F6Q4 Q5F6Q3 [40,41]
Streptococcus pyogenes M1 SF370 Spy0128, Spy0130, Spy0843, Spy1357, 
Spy1274, Spy1390, Spy0416, Spy2010, 
Spy2018
P60811 Q7DAL7 Q99ZD7 Q9A0C0 
Q9A180 Q9A1S0 Q9A1S2 P58099 
Q99XV0
[42]
Campylobacter jejuni NCTC 11168 FlaA, cjaA P56963 Q9PNV7 [43,44]
Helicobacter pylori J99 CagA, VacA, NAP Q9ZKW5 Q9ZLT1 Q9ZMJ1 [45]
Chlamydia pneumoniae CWL029 MOMP, Pmp2, ArtJ, HtrA, OmpH-like P27455 Q9Z3A1 Q9Z869 Q9Z6T0 
Q9Z8N7
[46,46]
Table 1: Tuning NERVE settings on a known dataset including 10 proteomes.
Pathogen Strain Known protective antigens (non 
cytoplasmic, ≤2 TMs)
Primary accession numbers 
(Uniprot database)
References
Bacillus anthracis AMES ANCESTOR PA83, Sap, EA1, AhpC P13423 P49051 P94217 Q81Y83 [7,22]
Pseudomonas aeruginosa ATCC 15692 OprI, OprF P11221 P13794 [23–25]
Yersinia pestis CO-92 Caf1, LcrV, YscF P26948 P21206 Q7ARI0 [26,27]
Streptococcus agalactiae V 2603 V/R Sip, GBS67, GBS80 Q8E2F6 Q8DYR5 Q8E0S9 [8]
Streptococcus agalactiae III NEM316 Sip, GBS67, GBS80, C5a-ase Q8E7W4 Q8E4C3 Q8E6E4 Q8E4T9 [8]
Streptococcus agalactiae Ia A909 Sip, GBS67, GBS80, C5a-ase, C protein 
alpha-antigen, C protein beta-antigen
Q3K3Z5 Q3K246 Q3K250 Q3K0M1 
Q02192 Q3K3P4
[8]
Neisseria meningitidis B MC58 NspA, PorA, TbpA, TbpB, GNA33, 
GNA992, NadA, App, GNA1870
Q7DDM2 Q51240 Q9K0U9 Q9K0V0 
Q7DDU3 Q7DDJ2 Q9JXK7 Q9JXL6 
Q9JXV4
[12]
Porphyromonas gingivalis W83 FimA, HagA, HagB, PG32, PG33 P59914 P59915 Q7MTI5 Q9S3R9 
Q9S3R8
[29–32]
Borrelia burgdorferi B31 OspA, OspC, BBI16 P14013 Q07337 O50870 [33–35]
Chlamydia trachomatis D UW-3/Cx MOMP, OMP3, OMP2 Q46409 P21355 P38006 [36]
Data concerning the ten proteomes used for tuning NERVE Figure 3
Data concerning the ten proteomes used for tuning 
NERVE. The number of selected VCs is reported beside the 
overall number of sequences. The average size of the 
selected VC pools is 8.17% of the proteome (min 5.09%, max 
10.73%).
Data concerning the six proteomes used to test NERVE set- tings Figure 4
Data concerning the six proteomes used to test 
NERVE settings. The number of selected VCs is reported 
beside the overall number of sequences. Average size of 
selected VCs pools is 9.32% of proteome (min 8,17%, max 
11,33%).BMC Biotechnology 2006, 6:35 http://www.biomedcentral.com/1472-6750/6/35
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Availability and requirements
Project name: NERVE
Home page: http://www.bio.unipd.it/molbinfo
This software is also available as an additional file [See
Additional file 1]
Operating system: Linux (tested distribution: Debian)
Programming language: Perl
Other requirements: Perl 5.8.7 or higher, PSORTb 2.0,
SPAAN
License: GNU GPL
Any restrictions to use by non-academics: licence needed
Abbreviations
MHC = major hystocompatibility complex; ORF = open
reading frame; PA = protective antigen; RV = Reverse Vac-
cinology; SP = shared peptide; TM = transmembrane helix;
VC = vaccine candidate.
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